

# Alberto Broniscer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2225037/publications.pdf>

Version: 2024-02-01

106  
papers

7,206  
citations

87888

38  
h-index

60623

81  
g-index

110  
all docs

110  
docs citations

110  
times ranked

7477  
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics of patients $\leq$ 10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. <i>Neuro-Oncology</i> , 2022, 24, 141-152.	1.2	9
2	The seventh international RASopathies symposium: Pathways to a cure—expanding knowledge, enhancing research, and therapeutic discovery. <i>American Journal of Medical Genetics, Part A</i> , 2022, 188, 1915-1927.	1.2	10
3	Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome. <i>Nature Cancer</i> , 2022, 3, 629-648.	13.2	16
4	IMMU-06. Landscape of adaptive immunity of childhood brain cancers. <i>Neuro-Oncology</i> , 2022, 24, i82-i82.	1.2	0
5	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). <i>Journal of Clinical Oncology</i> , 2021, 39, 822-835.	1.6	106
6	Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. <i>Clinical Cancer Research</i> , 2021, 27, 2879-2889.	7.0	35
7	TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma. <i>Frontiers in Immunology</i> , 2021, 12, 637146.	4.8	32
8	Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma. <i>Nature Communications</i> , 2021, 12, 4089.	12.8	27
9	[11C]-Methionine PET for Identification of Pediatric High-Grade Glioma Recurrence. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.120.261891.	5.0	4
10	The spectrum of rare central nervous system (CNS) tumors with <i>EWSR1</i> – <i>non-ETS</i> fusions: experience from three pediatric institutions with review of the literature. <i>Brain Pathology</i> , 2021, 31, 70-83.	4.1	29
11	Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab179.	0.7	5
12	Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 362-371.	2.4	17
13	Defining Optimal Target Volumes of Conformal Radiation Therapy for Diffuse Intrinsic Pontine Glioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 838-847.	0.8	7
14	Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report. <i>Neuro-Oncology</i> , 2020, 22, 1696-1704.	1.2	14
15	Improving long-term survival in diffuse intrinsic pontine glioma. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 647-658.	2.8	5
16	Molecular Heterogeneity and Cellular Diversity: Implications for Precision Treatment in Medulloblastoma. <i>Cancers</i> , 2020, 12, 643.	3.7	13
17	Clinical, imaging, and molecular analysis of pediatric pontine tumors lacking characteristic imaging features of DIPG. <i>Acta Neuropathologica Communications</i> , 2020, 8, 57.	5.2	32
18	Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition. <i>Acta Neuropathologica</i> , 2020, 139, 1071-1088.	7.7	50

#	ARTICLE	IF	CITATIONS
19	A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study. <i>Neuro-Oncology</i> , 2020, 22, 875-885.	1.2	53
20	Radiation dose response of neurologic symptoms during conformal radiotherapy for diffuse intrinsic pontine glioma. <i>Journal of Neuro-Oncology</i> , 2020, 147, 195-203.	2.9	5
21	Evaluation of <sup>11</sup> C-Methionine PET and Anatomic MRI Associations in Diffuse Intrinsic Pontine Glioma. <i>Journal of Nuclear Medicine</i> , 2019, 60, 312-319.	5.0	18
22	Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 829-838.	2.3	6
23	Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas. <i>Cancer Research</i> , 2019, 79, 4026-4041.	0.9	16
24	Is Schimmelpenning Syndrome Associated with Intracranial Tumors? A Case Report. <i>Pediatric Neurosurgery</i> , 2019, 54, 201-206.	0.7	2
25	H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo. <i>Acta Neuropathologica</i> , 2019, 137, 637-655.	7.7	85
26	Efficacy and Safety of Dabrafenib in Pediatric Patients with <i>BRAF</i> V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study. <i>Clinical Cancer Research</i> , 2019, 25, 7303-7311.	7.0	128
27	A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 7294-7302.	7.0	63
28	Malignant progression of a peripheral nerve sheath tumor in the setting of rhabdoid tumor predisposition syndrome. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27030.	1.5	3
29	Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27035.	1.5	36
30	Malignant rhabdoid tumors originating within and outside the central nervous system are clinically and molecularly heterogeneous. <i>Acta Neuropathologica</i> , 2018, 136, 315-326.	7.7	26
31	Bithalamic gliomas may be molecularly distinct from their unilateral high-grade counterparts. <i>Brain Pathology</i> , 2018, 28, 112-120.	4.1	26
32	Posttreatment DSC-MRI is Predictive of Early Treatment Failure in Children with Supratentorial High-Grade Glioma Treated with Erlotinib. <i>Clinical Neuroradiology</i> , 2018, 28, 393-400.	1.9	6
33	Mortality in children with low-grade glioma or glioneuronal tumors: A single-institution study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26717.	1.5	13
34	A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26832.	1.5	13
35	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. <i>Journal of Clinical Oncology</i> , 2018, 36, 1963-1972.	1.6	250
36	DIPG-45. RADIATION DOSE RESPONSE OF NEUROLOGIC SYMPTOM IMPROVEMENT DURING RADIOTHERAPY FOR DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2018, 20, i58-i58.	1.2	0

#	ARTICLE	IF	CITATIONS
37	Chemotherapy of Pediatric High-Grade Gliomas. , 2018, , 557-568.		0
38	Dabrafenib in pediatric patients with BRAF V600A positive high-grade glioma (HGG).. Journal of Clinical Oncology, 2018, 36, 10505-10505.	1.6	12
39	Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600A mutant relapsed refractory low-grade glioma.. Journal of Clinical Oncology, 2018, 36, 10506-10506.	1.6	17
40	Phase 1 trial of trametinib alone and in combination with dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 (NF1) progressive plexiform neurofibromas (PN).. Journal of Clinical Oncology, 2018, 36, 10537-10537.	1.6	20
41	11C-Methionine positron emission tomography delineates non-contrast enhancing tumor regions at high risk for recurrence in pediatric high-grade glioma. Journal of Neuro-Oncology, 2017, 132, 163-170.	2.9	19
42	Rapid and fulminant leptomeningeal spread following radiotherapy in diffuse intrinsic pontine glioma. Pediatric Blood and Cancer, 2017, 64, e26416.	1.5	11
43	Prognostic Relevance of Treatment Failure Patterns in Pediatric High-Grade Glioma: Is There a Role for a Revised Failure Classification System?. International Journal of Radiation Oncology Biology Physics, 2017, 99, 450-458.	0.8	8
44	Treatment-Related Noncontiguous Radiologic Changes in Children With Diffuse Intrinsic Pontine Glioma Treated With Expanded Irradiation Fields and Antiangiogenic Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1295-1305.	0.8	3
45	Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant. Drug Metabolism and Disposition, 2016, 44, 1116-1122.	3.3	15
46	Clinical Characteristics and Long-Term Outcomes of Movement Disorders in Childhood Thalamic Tumors. Pediatric Neurology, 2016, 65, 71-77.	2.1	4
47	Metastatic Low-Grade Gliomas in Children: 20 Years' Experience at St. Jude Children's Research Hospital. Pediatric Blood and Cancer, 2016, 63, 62-70.	1.5	42
48	Children with minimal chance for cure: parent proxy of the child's health-related quality of life and the effect on parental physical and mental health during treatment. Journal of Neuro-Oncology, 2016, 129, 373-381.	2.9	23
49	Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas. Acta Neuropathologica, 2016, 131, 299-307.	7.7	38
50	Pubertal development and primary ovarian insufficiency in female survivors of embryonal brain tumors following risk-adapted craniospinal irradiation and adjuvant chemotherapy. Pediatric Blood and Cancer, 2015, 62, 329-334.	1.5	20
51	Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nature Genetics, 2015, 47, 263-266.	21.4	109
52	Incidental diagnosis of diffuse intrinsic pontine glioma in children. Pediatric Blood and Cancer, 2015, 62, 1081-1083.	1.5	4
53	Malignant Transformation of Low-Grade Gliomas in Children: Lessons Learned From Rare Medical Events. Journal of Clinical Oncology, 2015, 33, 978-979.	1.6	9
54	Cervicomedullary tumors in children. Journal of Neurosurgery: Pediatrics, 2015, 16, 357-366.	1.3	29

#	ARTICLE	IF	CITATIONS
55	Pulmonary Function After Treatment for Embryonal Brain Tumors on SJMB03 That Included Craniospinal Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 47-53.	0.8	14
56	Subsequent neoplasms in survivors of childhood central nervous system tumors: risk after modern multimodal therapy. <i>Neuro-Oncology</i> , 2015, 17, 448-456.	1.2	44
57	Phase 1 study of dabrafenib in pediatric patients (pts) with relapsed or refractory <i>BRAF</i> V600E high- and low-grade gliomas (HGG, LGG), Langerhans cell histiocytosis (LCH), and other solid tumors (OST).. <i>Journal of Clinical Oncology</i> , 2015, 33, 10004-10004.	1.6	27
58	Developmental pharmacokinetics of topotecan (TPT), a renally excreted drug, in infants and young children with brain tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10055-10055.	1.6	0
59	Management of diffuse intrinsic pontine glioma in children: current and future strategies for improving prognosis. <i>CNS Oncology</i> , 2014, 3, 421-431.	3.0	21
60	Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas. <i>Frontiers in Oncology</i> , 2014, 4, 67.	2.8	31
61	ED-27 * CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME IN MOVEMENT DISORDER IN CHILDHOOD THALAMIC TUMORS. <i>Neuro-Oncology</i> , 2014, 16, v71-v72.	1.2	0
62	Effect of time from diagnosis to start of radiotherapy on children with diffuse intrinsic pontine glioma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1180-1183.	1.5	9
63	Prospective evaluation of local control and late effects of conformal radiation therapy in children, adolescents, and young adults with high-grade glioma. <i>Neuro-Oncology</i> , 2014, 16, 1652-1660.	1.2	21
64	Determination of crizotinib in human and mouse plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI MS/MS). <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 960, 151-157.	2.3	21
65	Occult post-contrast signal enhancement in pediatric diffuse intrinsic pontine glioma is the MRI marker of angiogenesis?. <i>Neuroradiology</i> , 2014, 56, 405-412.	2.2	25
66	Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. <i>Neuro-Oncology</i> , 2014, 16, 848-855.	1.2	62
67	The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. <i>Nature Genetics</i> , 2014, 46, 444-450.	21.4	871
68	First-in-pediatrics phase I study of crenolanib besylate (CP-868,596-26) administered during and after radiation therapy (RT) in newly diagnosed diffuse intrinsic pontine glioma (DIPG) and recurrent high-grade glioma (HGG).. <i>Journal of Clinical Oncology</i> , 2014, 32, 10064-10064.	1.6	5
69	Clinico-radiologic characteristics of long-term survivors of diffuse intrinsic pontine glioma. <i>Journal of Neuro-Oncology</i> , 2013, 114, 339-344.	2.9	48
70	Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1552-1556.	1.5	3
71	Bereaved Parents' Intentions and Suggestions about Research Autopsies in Children with Lethal Brain Tumors. <i>Journal of Pediatrics</i> , 2013, 163, 581-586.	1.8	25
72	Phase I Trial, Pharmacokinetics, and Pharmacodynamics of Vandetanib and Dasatinib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma. <i>Clinical Cancer Research</i> , 2013, 19, 3050-3058.	7.0	82

#	ARTICLE	IF	CITATIONS
73	Novel Oncogenic <i>PDGFRA</i> Mutations in Pediatric High-Grade Gliomas. <i>Cancer Research</i> , 2013, 73, 6219-6229.	0.9	189
74	Pulmonary function after treatment for embryonal brain tumors on SJMB03 that included craniospinal irradiation.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10021-10021.	1.6	0
75	Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. <i>Nature Genetics</i> , 2012, 44, 251-253.	21.4	1,402
76	Determination of vandetanib in human plasma and cerebrospinal fluid by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 2561-2566.	2.3	25
77	A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: A report from the Pediatric Brain Tumor Consortium. <i>Neuro-Oncology</i> , 2011, 13, 290-297.	1.2	110
78	Genome-Wide Analyses Identify Recurrent Amplifications of Receptor Tyrosine Kinases and Cell-Cycle Regulatory Genes in Diffuse Intrinsic Pontine Glioma. <i>Journal of Clinical Oncology</i> , 2011, 29, 3999-4006.	1.6	286
79	Characterization, Treatment, and Outcome of Intracranial Neoplasms in the First 120 Days of Life. <i>Journal of Child Neurology</i> , 2011, 26, 988-994.	1.4	21
80	Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. <i>Neuro-Oncology</i> , 2011, 13, 298-306.	1.2	76
81	Three-dimensional susceptibility-weighted imaging and two-dimensional T2*-weighted gradient-echo imaging of intratumoral hemorrhages in pediatric diffuse intrinsic pontine glioma. <i>Neuroradiology</i> , 2010, 52, 1167-1177.	2.2	57
82	Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma. <i>Cancer</i> , 2010, 116, 4632-4637.	4.1	70
83	Irradiation of Pediatric High-Grade Spinal Cord Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1451-1456.	0.8	29
84	Integrated Molecular Genetic Profiling of Pediatric High-Grade Gliomas Reveals Key Differences With the Adult Disease. <i>Journal of Clinical Oncology</i> , 2010, 28, 3061-3068.	1.6	558
85	Phase I Study of Vandetanib During and After Radiotherapy in Children With Diffuse Intrinsic Pontine Glioma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4762-4768.	1.6	108
86	A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. <i>European Journal of Cancer</i> , 2010, 46, 3287-3293.	2.8	59
87	Pediatric low-grade gliomas and the need for new options for therapy: why and how?. <i>Cancer Biology and Therapy</i> , 2009, 8, 4-10.	3.4	45
88	Phase I and Pharmacokinetic Studies of Erlotinib Administered Concurrently with Radiotherapy for Children, Adolescents, and Young Adults with High-Grade Glioma. <i>Clinical Cancer Research</i> , 2009, 15, 701-707.	7.0	64
89	Pharmacokinetics of Erlotinib for the Treatment of High-Grade Glioma in a Pediatric Patient with Cystic Fibrosis: Case Report and Review of the Literature. <i>Pharmacotherapy</i> , 2009, 29, 858-866.	2.6	13
90	Bone marrow transplantation for severe aplastic anemia secondary to temozolomide. <i>Journal of Neuro-Oncology</i> , 2009, 91, 237-239.	2.9	14

#	ARTICLE	IF	CITATIONS
91	Young age may predict a better outcome for children with diffuse pontine glioma. <i>Cancer</i> , 2008, 113, 566-572.	4.1	54
92	Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. <i>Neuro-Oncology</i> , 2008, 10, 341-347.	1.2	46
93	Phase I and Pharmacokinetic Study of the Oral Farnesyltransferase Inhibitor Lonafarnib Administered Twice Daily to Pediatric Patients With Advanced Central Nervous System Tumors Using a Modified Continuous Reassessment Method: A Pediatric Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 3137-3143.	1.6	67
94	Survival and Late Mortality in Long-Term Survivors of Pediatric CNS Tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 1532-1538.	1.6	45
95	Clinical and Molecular Characteristics of Malignant Transformation of Low-Grade Glioma in Children. <i>Journal of Clinical Oncology</i> , 2007, 25, 682-689.	1.6	200
96	Phase I Trial of Single-Dose Temozolomide and Continuous Administration of <i>6</i> -Benzylguanin in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report. <i>Clinical Cancer Research</i> , 2007, 13, 6712-6718.	7.0	62
97	Plasma and Cerebrospinal Fluid Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420. <i>Clinical Cancer Research</i> , 2007, 13, 1511-1515.	7.0	89
98	Temozolomide after Radiotherapy for Newly Diagnosed High-grade Glioma and Unfavorable Low-grade Glioma in Children. <i>Journal of Neuro-Oncology</i> , 2006, 76, 313-319.	2.9	76
99	Intratumoral hemorrhage among children with newly diagnosed, diffuse brainstem glioma. <i>Cancer</i> , 2006, 106, 1364-1371.	4.1	36
100	Past, Present, and Future Strategies in the Treatment of High-Grade Glioma in Children. <i>Cancer Investigation</i> , 2006, 24, 77-81.	1.3	34
101	Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children. <i>Cancer</i> , 2005, 103, 133-139.	4.1	101
102	Second neoplasms in pediatric patients with primary central nervous system tumors. <i>Cancer</i> , 2004, 100, 2246-2252.	4.1	101
103	Supratentorial High-Grade Astrocytoma and Diffuse Brainstem Glioma: Two Challenges for the Pediatric Oncologist. <i>Oncologist</i> , 2004, 9, 197-206.	3.7	199
104	Radiation Therapy and High-Dose Tamoxifen in the Treatment of Patients With Diffuse Brainstem Gliomas: Results of a Brazilian Cooperative Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 1246-1253.	1.6	64
105	Brain Stem Involvement in Children with Neurofibromatosis Type 1: Role of Magnetic Resonance Imaging and Spectroscopy in the Distinction from Diffuse Pontine Glioma. <i>Neurosurgery</i> , 1997, 40, 331-338.	1.1	44
106	Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor. <i>Neuro-Oncology</i> , 0, , .	1.2	7